Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30345292 | 1.00 | IDO1 (0.37) | IDO1MAPTGAANOS3NOS1 | |
| SCHEMBL7042571 | 0.82 | NOS3 (0.41) | MAPTNOS3NOS1NOS2PTGS2 | |
| SCHEMBL1437868 | 0.82 | PTGS2 (0.39) | IDO1MAPTPTGS2TP53TAAR1 | |
| SCHEMBL811745 | 0.82 | IDO1 (0.44) | IDO1MAPTNOS3NOS1NOS2 | |
| SCHEMBL397098 | 0.82 | NOS3 (0.41) | MAPTGAANOS3NOS1NOS2 | |
| SCHEMBL24661052 | 0.78 | IDO1 (0.38) | IDO1MAPTGAAALDH1A1TSHR | |
| SCHEMBL11437281 | 0.78 | IDO1 (0.43) | IDO1MAPTGAAALDH1A1ALOX15 | |
| Nitrogen SCHEMBL28571594 | 0.77 | NOS3 (0.38) | MAPTNOS3NOS1NOS2PTGS2 | |
| Nitrogen SCHEMBL27562848 | 0.77 | PTGS2 (0.36) | IDO1MAPTPTGS2TP53TAAR1 | |
| SCHEMBL12671466 | 0.76 | IDO1 (0.37) | IDO1MAPTGAAALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5846990-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB CO. (US) | 1998-12-08 | — | — | US | claimed |
| US-20230126352-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | ONCODESIGN SA (FR) | 2023-04-27 | — | — | US | disclosed |
| US-10766869-B2 | Triazoles for the treatment of demyelinating dieases | VERTEX PHARMACEUTCALS INCORPORATED (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190185436-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMA (US) | 2019-06-20 | — | — | US | disclosed |
| US-5739133-A | N-ACYLATED AND ALKYLATED DERIVATIVES OF PYRIDAZINO(4,5-B)-QUINOLINES; EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS; STROKES; ANTIISCHEMIC AND HYPOGLYCEMIC AGENTS; PSYCHOSIS; NEUROGODEGENERATIVE DISORDERS | ZENECA LIMITED (GB) | 1998-04-14 | — | — | US | disclosed |
| US-5733910-A | Pyridazinedione compounds useful in the treating neurological disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1998-03-31 | — | — | US | disclosed |
| US-5606063-A | NMDA antagonists | MERRELL PHARMACEUTICALS INC. (US) | 1997-02-25 | — | — | US | disclosed |
| US-5604227-A | EXCITATORY AMINO ACID ANTAGONIST; MONO, DI OR TRI-ACETYLATION OR ALKYLATION | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1997-02-18 | — | — | US | disclosed |
| US-5599814-A | SUBSTITUTED PYRIDAZINO(4,5-B)QUINOLINES AS ANTAGONISTS OF EXCITATORY AMINO ACIDS | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1997-02-04 | — | — | US | disclosed |
| EP-0516297-B1 | Pyridazinediones and their use in the treatment of neurological disorders | ZENECA LTD (GB) | 1996-10-30 | — | — | EP | disclosed |
| EP-0573562-B1 | Dihydroquinoline NMDA antagonists | MERRELL PHARMA INC (US) | 1996-04-24 | — | — | EP | disclosed |
| EP-0573562-A1 | NMDA ANTAGONISTS. | MERRELL DOW PHARMA (US) | 1993-12-15 | — | — | EP | disclosed |
| US-5270309-A | Kynurenic acid derivatives useful in the treatment of neurodegenerative disorders | MERCK SHARP & DOHME LIMITED (GB) | 1993-12-14 | — | — | US | disclosed |
| EP-0303387-B1 | KYNURENIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 1993-04-21 | — | — | EP | disclosed |
| EP-0516297-A1 | Pyridazinediones and their use in the treatment of neurological disorders | ZENECA LIMITED (GB) | 1992-12-02 | — | — | EP | disclosed |
| WO-1992015565-A1 | NMDA ANTAGONISTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-09-17 | — | — | WO | disclosed |
| EP-0303387-A1 | Kynurenic acid derivatives useful in the treatment of neurodegenerative disorders | MERCK SHARP & DOHME LTD. (GB) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766869-B2 | Triazoles for the treatment of demyelinating dieases | PMP22, MYT1, IDE | IDO1 5/4885MAPT 421/4885GAA 961/4885 |
| US-20190185436-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | PMP22, MYT1, IKZF3 | IDO1 12/4885MAPT 168/4885GAA 1359/4885 |
| US-20230126352-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | RIPK2, RIPK1, RIPK3 | IDO1 3917/4885MAPT 2467/4885GAA 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.